Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. Takeda Pharmaceuticals U.S.A., Inc.
CRL
•Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc. – FDA CRL

Record Details

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Takeda Pharmaceuticals, U.S.A., Inc. regarding its Biologics License Application (BLA) 761133 for MLNO0002 SC, originally submitted on March 7, 2019. The FDA determined that the application cannot be approved in its present form due to significant product quality deficiencies, primarily related to human factors (HF) validation of the Entyvio prefilled pen.

The main violations stemmed from a submitted human factors validation study that identified numerous use errors, close calls, and use difficulties with critical and non-critical tasks. Takeda had not implemented sufficient revisions to the product user interface to address these identified issues. The FDA provided detailed recommendations for improving the device design, device label/labeling, and the Instructions for Use (IFU). Specific IFU concerns included lack of clarity in figures, inaccurate depiction of injection sites, insufficient emphasis on critical warnings, unclear end-of-injection cues, and inadequate prominence for important information regarding storage, preparation, and device safety.

Required actions include implementing the FDA's recommended user interface revisions and conducting a new human factors validation study to demonstrate the effectiveness of these mitigations. Takeda must also submit updated Prescribing Information in structured product labeling (SPL) format and revise carton and container labeling, specifically by bolding storage statements and clarifying the expiration date format for improved user comprehension.

Company
Takeda Pharmaceuticals U.S.A., Inc.
Product type
BLA
Office
Division of Gastroenterology and Inborn Errors
Person
  • Mayuresh Gadre
View Company Profile

ID · 973c4fb1-7870-473f-8565-9e4e6b2f61ff

Other documents for Takeda Pharmaceuticals U.S.A., Inc.
  • 483 - 2020-03-18March 18, 2020
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Takeda Pharmaceuticals U.S.A., Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.